1、Breaking the Bottleneck in Cardiovascular Drug R&D | Highly Predictive Animal Models Accelerate Preclinical Efficacy Validation

• –Industry Pain Poin:Traditional cardiovascular disease models feature low clinical translation rates and fail to accurately simulate human pathophysiological characteristics, leading to prolonged drug R&D cycles and high failure rates.
• –Value Proposition: Highly predictive animal models based on in-depth phenotypic analysis, combined with a multi-dimensional efficacy evaluation system, shorten the R&D cycle by 30% and reduce the risk of clinical failure.

2、Service Overview

• The core challenge in cardiovascular disease drug R&D lies in the pathophysiological differences between animal models and human diseases. Traditional models are unable to replicate complex cardiovascular pathological features (e.g., myocardial ischemia-reperfusion injury, atherosclerotic plaque stability), resulting in insufficient predictability of preclinical data.
• Jenniohas built a highly human-relevant preclinical platform for cardiovascular diseases through precision surgical models (e.g., LAD ligation-induced myocardial infarction) and genetically engineered models (e.g., spontaneously hypertensive rats), integrated with dynamic functional monitoring (echocardiography, hemodynamics) and molecular pathological verification, which provides pharmaceutical companies with full-chain data support from target validation to IND filing.

3、Our Services

1. Ischemic Heart Disease Models

• Myocardial Infarction Model: By ligating the left anterior descending coronary artery (LAD) in SD rats through thoracotomy, myocardial ischemia/reperfusion injury is mimicked, thereby evaluating the effects of drugs on infarct size, cardiac function (LVEF), and myocardial fibrosis.
• Endpoint Indicators: Electrocardiogram (ECG), serum markers (cTnI), histopathology (Masson’s staining), echocardiography.

2. Heart Failure Models

• Pressure Overload Model: Aortic constriction (TAC) to induce heart failure, for assessing the improvement effects of drugs on ventricular remodeling, BNP levels and survival rate.
• Metabolic Heart Failure Model: High-fat diet combined with STZ induction to establish diabetic cardiomyopathy in db/db mice, for detecting fasting blood glucose, insulin resistance and myocardial lipid deposition.

3. Infectious Cardiovascular Disease Models

• Endocarditis Model:Intravenous injection of Staphylococcus aureus (3×10⁵ CFU) in rats after cardiac intubation to simulate acute infective endocarditis, for evaluating the efficacy of antibiotics or anti-inflammatory drugs on bacterial load and valvular damage.
• Detection Indicators: Blood culture colony count, tissue HE staining, inflammatory factors (IL-6, TNF-α)

4、Technology Platforms and Advantages

Technology Platforms

• High-precision Surgical Modeling:Microsurgical techniques ensure a success rate of over 95% for LAD ligation/aortic constriction and a postoperative survival rate of ≥90%.
• Dynamic Functional Monitoring: Small animal ultrasound (Vevo® 3100) for real-time tracking of cardiac function changes; small animal blood pressure monitoring system for continuous in vivo blood pressure monitoring.
• Multi-omics Analysis: Transcriptome sequencing and proteomics of myocardial tissue (e.g., cardiac troponin pathway) to reveal the mechanism of drug action.

Differentiated Advantages

• Clinical Relevance of Models:Pathological features (fibrosis, inflammatory infiltration) of the myocardial infarction model are highly consistent with human acute myocardial infarction (AMI).
• One-stop Efficacy Evaluation:Integration of hemodynamics, imaging, molecular pathology and survival analysis, outputting FDA/EMA-compatible data reports.

5、Service Process

• Demand Alignment (1 working day): Customization of protocols (model selection, administration route, endpoint indicators).
• Model Construction and Drug Administration (4-8 weeks):Surgical modeling in SPF animal facility and GLP-aligned drug administration management.
• Real-time Data Synchronization: Exclusive online platform for sharing ultrasound images, behavioral videos and raw data.
• Report Delivery (2 weeks):Final report including statistical analysis, histopathological atlas and mechanism interpretation.

6、Quality Control and Compliance

• Standard Adherence: Experimental operations comply with AAALAC welfare standards, and data management meets the recording requirements of relevant declaration criteria.
• Quality Control Nodes:SOP video review for surgical operations; double-blind scoring for histopathology; three-level audit of raw data.
• Facility Certification: SPF animal facility (GB 14925-2010), ISO 9001 quality management system.

7、Case Studies

Project Name: Efficacy Validation of an Anti-fibrotic Drug in a Myocardial Infarction Model

• Model: LAD ligation in SD rats (n=10/group)
• Intervention: Candidate drug vs. positive control (Captopril), administered for 4 weeks
• Results:
  • 38% reduction in infarct size in the drug group (p<0.01), 50% increase in LVEF (vs. model group); 20% decrease in LVEDD (vs. model group); 30% decrease in LVESD.
  • Left: Extensive blue-stained fibrosis in the model group; Right: Significant reduction in fibrosis in the drug group.

8、Cooperation Advantages

• Full-cycle Support:
  • From model customization to the compilation of declaration materials.
• Efficient Delivery:
  • Streamlined delivery schedule, with urgent projects launched within 2 weeks.
• Cost Optimization:
  • Shared model library resources, reducing animal costs for single projects by 30%.

9、FAQ

• Q: Are non-human primate cardiovascular models supported?
• A: Currently, rat, mouse and rabbit models (e.g., hypercholesterolemic rabbits) are available; non-human primate models require custom development.
• Q: Can in vitro drug screening with cardiac organoids be integrated?
• A: Yes! We can connect with the 3D myocardial organoid platform for lead compound primary screening (protocol available upon separate inquiry).

10、Laboratory Highlights

• Core Equipment:
  • Small animal ventilator, stereotaxic apparatus, stereomicroscope, high-frequency electrocautery, ensuring microsurgical precision and animal welfare.

• Detection Platforms:
  • • Small animal echocardiography, small animal blood pressure monitoring system, small animal ECG, small animal PET-CT (molecular imaging), Luminex multiplex cytokine assay (inflammatory pathway analysis).

View More

11、Contact Us

Get a Customized Proposal Now

• Email: 3691125803@qq.com
• Tel: +86 18802035152

Resource Download

• Technical Manual for Cardiovascular Disease Models
• SOP for Myocardial Infarction Model Construction